AI주식인사이트AI Stock Insight
B

듀켐바이오

176750KOSDAQ

60.5 / 100

Reference Date: 2026-10-23

Financial Score21.0 / 40
News Sentiment12.5 / 25
Momentum17.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Surged 42.5% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Dukem Bio is a company specializing in the development, manufacturing, and sales of radiopharmaceuticals for cancer and brain diseases, holding the largest number of PET-CT radiopharmaceutical products in South Korea. In 2025, it achieved revenue of 38.57 billion won and operating profit of 7.44 billion won, maintaining a market share leadership in key product lines such as FDG and Alzheimer's diagnostic agents. By acquiring RadioDnS Labs in 2024, the company is enhancing its R&D capabilities and aiming to become a global leader in radiopharmaceuticals.

Number of Employees

144people

Average Salary

44.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
35.90Industry Average 15.000.0Point

2.4x industry avg (risky)

PBR
4.76Industry Average 1.200.0Point

4.0x industry avg (risky)

ROE
14.05Industry Average 8.005.5Point

1.8x industry avg (good)

Debt Ratio
20.42Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2024~20257.5 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲8.3% (1-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲46.6% (1-year basis)

ROE Trend
2.5 / 4

Avg ROE 19.4% (declining, 2yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position5.0Point

52w mid range (44%)

Current 8,220Won52-week high 11,68052-week low 5,440
1-month return6.0Point

1m +42.46% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral합병등종료보고서(합병)2026-10-02